Patents Issued in November 19, 2019
  • Patent number: 10478421
    Abstract: Provided herein are compounds and formulations thereof that can be capable of binding to sortilin or an analogue thereof. Also provided herein are methods of administering the compounds and formulation provided herein to a subject in need thereof.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: November 19, 2019
    Assignees: University of Florida, University of Rochester
    Inventors: Robert Pleasants Sparks, Wayne Charles Guida, Janet Lindsay DeHoff-Sparks
  • Patent number: 10478422
    Abstract: An aspect of the present disclosure is directed to an oral liquid composition comprising valsartan with enhanced solubility and stability. Other aspects are directed to methods of using the oral liquid compositions for the treatment of hypertension, treatment of heart failure and reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: November 19, 2019
    Assignee: ECI PHARMACEUTICALS, LLC
    Inventor: Greg Thomas
  • Patent number: 10478423
    Abstract: The present invention relates to substituted indazole compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by degulated protein kinase activity, like cancer. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such these compounds or the pharmaceutical compositions containing them.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: November 19, 2019
    Assignee: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Andrea Lombardi Borgia, Marina Ciomei, Daniele Donati, Marcella Nesi
  • Patent number: 10478424
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: November 19, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alaric J. Dyckman, Dharmpal S. Dodd, Christopher P. Mussari, Laxman Pasunoori, Sreekantha Ratna Kumar
  • Patent number: 10478425
    Abstract: Provided is a compound which is useful as an AMPK activator. The compound is represented by formula: wherein the symbols are defined in the specification.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: November 19, 2019
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Yuusuke Tamura, Hiroki Ozasa
  • Patent number: 10478426
    Abstract: This invention relates to novel substituted benzamide according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: November 19, 2019
    Assignee: GLAXOSMITHKLINE LLC
    Inventors: Joelle Lorraine Burgess, Steven David Knight
  • Patent number: 10478427
    Abstract: A therapeutic agent for fibrosis, whose active ingredient is constituted by a glucosylceramide synthase inhibitor or lactosylceramide synthase inhibitor, or both, inhibits the nuclear translocation of phosphorylated Smad, thereby treating and preventing fibrosis.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: November 19, 2019
    Assignee: NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY
    Inventors: Hiroyuki Nakamura, Toshihiko Murayama
  • Patent number: 10478428
    Abstract: Combination therapies for treating cancer comprising administration of a topoisomerase-1 inhibitor and a PARP inhibitor are provided. The topoisomerase-1 inhibitor can be delivered as a liposomal formulation that provides for prolonged accumulation of the topoisomerase-1 inhibitor within a tumor relative to outside of the tumor. Therapeutic benefit can thereby be obtained by delaying the administration of the PARP inhibitor after each administration of a liposomal irinotecan formulation until the accumulation of the topoisomerase inhibitor in the tumor is sufficiently greater than outside the tumor to result in increased efficacy of the PARP inhibitor and topoisomerase inhibitor within the tumor, while reducing the peripheral toxicity of the combination therapy. The therapies disclosed herein are useful in the treatment of human cancers with solid tumors, including cervical cancer.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: November 19, 2019
    Assignee: Ipsen Biopharm Ltd.
    Inventors: Sarah F. Blanchette, Daryl C. Drummond, Jonathan Basil Fitzgerald, Victor Moyo
  • Patent number: 10478429
    Abstract: Described herein are oral abuse deterrent pharmaceutical compositions, methods for making the same, and methods for treating pain by administering the pharmaceutical composition to a subject in need thereof. In particular, an oral abuse deterrent pharmaceutical composition comprising a soft capsule and a controlled release matrix comprising oxycodone are described.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: November 19, 2019
    Assignee: Patheon Softgels, Inc.
    Inventors: Justin Hughey, Saujanya Gosangari, Chue Hue Yang
  • Patent number: 10478430
    Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase and combination therapies thereof. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: wherein the variables are as defined herein.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: November 19, 2019
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: John Robert Pollard, Philip Michael Reaper, Mohammed Asmal
  • Patent number: 10478431
    Abstract: The present disclosure provides a method for inhibiting cytomegalovirus (CMV) replication in a cell infected with CMV, the method comprising contacting the cell with a bisbenzimidazole compound. The present disclosure provides a method of treating a CMV infection in an individual, the method comprising administering to the individual an effective amount of a bisbenzimidazole compound.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: November 19, 2019
    Assignee: The J. David Gladstone Institutes
    Inventor: Leor S. Weinberger
  • Patent number: 10478432
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: November 19, 2019
    Assignees: Unity Biotechnology, Inc., Buck Institute for Research on Aging, Mayo Foundation for Medical Education and Research
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Darren J. Baker, Bennett G. Childs, Jan M. A. van Deursen
  • Patent number: 10478433
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: November 19, 2019
    Assignees: Unity Biotechnology, Inc., Buck Institute for Research on Aging, Mayo Foundation for Medical Education and Research
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Darren J. Baker, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Jan M. A. van Deursen, Alain Philippe Vasserot, Bennett G. Childs
  • Patent number: 10478434
    Abstract: Processes for providing depot injections of recrystallized aripiprazole lauroxil in which particles of the aripiprazole lauroxil have a surface area of about 0.50 to about 3.3 m2/g; and crystals of aripiprazole lauroxil produced by such processes.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: November 19, 2019
    Assignee: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Wilfredo Morales, Tarek A. Zeidan, Renato A. Chiarella, Steven G. Wright, Jason M. Perry
  • Patent number: 10478435
    Abstract: Described herein are methods of treatment of stroke and traumatic brain injury comprising administration of a CRAC channel inhibitor.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: November 19, 2019
    Assignees: CALCIMEDICA, INC., THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Kenneth Stauderman, Michael Dunn, Sudarshan Hebbar, Midori Yenari, Rachid Kacimi
  • Patent number: 10478436
    Abstract: Methods for treating Down syndrome and improving cognitive function of a patient with an intellectual disability are disclosed. 5-hydroxytryptamine sub-receptor six (5-HT6) receptor antagonists are provided for improving the cognition of a Down syndrome patient.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: November 19, 2019
    Assignee: THE UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Julie Ruth Korenberg, Karen Sue Wilcox, Peter Jeffrey West, Raymond Pierre Kesner
  • Patent number: 10478437
    Abstract: The present invention relates to compositions and methods for reducing cell proliferation and/or promoting cell death. It is based, at least in part, on the discovery that in platinum drug-resistant cell lines, certain compounds, together with a second antiproliferative agent (e.g., cisplatin), act synergistically to promote apoptosis. Accordingly, the present invention provides for novel anticancer strategies.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: November 19, 2019
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Wei Qian, Peter Wipf, Bennett Van Houten
  • Patent number: 10478438
    Abstract: A method of treating exposure to organophosphate agents and preventing morbidity due to such exposure through the administration of a pyrazolopyrimidine compound such as ocinaplon, zaleplon, indiplon, or divaplon.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: November 19, 2019
    Inventors: David Reed Helton, Ernest Pfadenhauer
  • Patent number: 10478439
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: November 19, 2019
    Assignee: Pharmacyclics LLC
    Inventors: Lee Honigberg, David J. Loury
  • Patent number: 10478440
    Abstract: The present invention provides a pharmaceutical composition for inhibiting angiogenesis containing a plant-derived natural compound which can be effective for preventing or treating disorders or diseases associated with angiogenesis. The compound used as an active ingredient in the pharmaceutical composition of the present invention suppresses VEGF-induced angiogenic responses without cytotoxicity at a low concentration by inhibiting the expression of an anti-angiogenic factor (for example, VEGF), and thus remarkably improves the safety of a drug.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: November 19, 2019
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Ho Jeong Kwon, Yong Hyo Kim
  • Patent number: 10478441
    Abstract: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: November 19, 2019
    Assignees: THE KATHOLIEKE UNIVERSITEIT LEUVEN, UNIVERSITY HOSPITAL ANTWERP
    Inventors: Berten Ceulemens, Lieven Lagae
  • Patent number: 10478442
    Abstract: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: November 19, 2019
    Assignees: THE KATHOLIEKE UNIVERSITEIT LEUVEN, UNIVERSITY HOSPITAL ANTWERP
    Inventors: Berten Ceulemens, Lieven Lagae
  • Patent number: 10478443
    Abstract: Novel methods for treating or reducing the likelihood of acquiring vaginal dysfunctions, more particularly vaginal dryness and dyspareunia, leading to sexual dysfunction and low sexual desire and performance, in susceptible warm-blooded animals including humans involving administration of a sex steroid precursor. Further administration of estrogen or selective estrogen receptor modulator, particularly those selected from the group consisting of Raloxifene, Arzoxifene, Tamoxifen, Droloxifene, Toremifene, Iodoxifene, GW 5638, TSE-424, ERA-923, and lasofoxifene, and more particularly compounds having the general structure: is specifically disclosed for the medical treatment and/or inhibition of development of some of these above-mentioned diseases. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: November 19, 2019
    Assignee: ENDORECHERCHE, INC.
    Inventors: Mohamed El-Alfy, Fernand Labrie, Louise Berger
  • Patent number: 10478444
    Abstract: A method of treating or preventing a systemic viral infection in a mammal by administering a pharmaceutically acceptable composition selected from the group consisting of squalamine, an active isomer thereof, and an active analogue thereof, via a dosing regimen that delivers effective antiviral concentrations of squalamine. Also compositions for achieving the systemic antiviral effect.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: November 19, 2019
    Assignee: Enterin, Inc.
    Inventor: Michael Zasloff
  • Patent number: 10478445
    Abstract: Disclosed herein are compounds, compositions and methods for the treatment of a disease or disorder related to activation of deacetylase enzymes. The compounds and methods are related to boronic acid derivatives of resveratrol. In some forms, the compound, compositions and methods relate to treatment of prostate cancer, colon cancer, or breast cancer, a cardiovascular disease, inflammation, obesity, diabetes, or a neurodegenerative disease.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: November 19, 2019
    Assignee: Georgetown University
    Inventors: Insoo Bae, Yong Weon Yi, Hyo Jin Kang, Hee Jeong Kim
  • Patent number: 10478446
    Abstract: Polycystic kidney disease is a cystic genetic disorder of the kidneys. Recent identification of signaling cascades de-regulated in PKD has led to the initiation of several clinical trials, but an effective therapy is still lacking. A new therapeutic paradigm is capable of improving the proliferation rate and cystic kidney volume in PKD.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: November 19, 2019
    Assignees: FONDAZIONE CENTRO SAN RAFFAELE OFFICE OF BIOTECHNOLOGY TRANSFER, FONDAZIONE TELETHON
    Inventors: Alessandra Boletta, Marco Chiaravalli, Isaline Severine Marie-Josephe Rowe
  • Patent number: 10478447
    Abstract: The disclosure provides an oral antiviral supplement composition comprising a lysine, an ascorbic compound, a flavonoid glycoside, a threonine, and a pyridoxine. The disclosure also provides a method of reducing viral replication in a cell comprising treating a virus-infected cell with a composition of the disclosure. The disclosure further provides a method for the treatment and prophylaxis of a viral infection in a patient comprising administering a composition of the disclosure.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: November 19, 2019
    Assignee: Vymedic, LLC
    Inventors: Kenneth E. Phillips, Cynthia A. Winning
  • Patent number: 10478448
    Abstract: Disclosed herein are antisense compounds and methods for decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) or Lp(a). Certain diseases, disorders or conditions related to apo(a) or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The antisense compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: November 19, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Susan M. Freier, Marc Lim, Andrew Dibble
  • Patent number: 10478449
    Abstract: Compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers includes a modified sugar and/or backbone modification. In some embodiments the modification is a 2?-OCH3 substituent group on a sugar moiety. Oligomer/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex (RISC), wherein at least one nucleotide of the oligomer has a modified sugar and/or backbone modification.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: November 19, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventor: Stanley T. Crooke
  • Patent number: 10478450
    Abstract: The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: November 19, 2019
    Assignee: Luitpold Pharmaceuticals, Inc.
    Inventors: Mary Jane Helenek, Marc L. Tokars, Richard P. Lawrence
  • Patent number: 10478451
    Abstract: The present embodiments relate to the use of dextran sulfate formulated for systemic administration for treatment, inhibition or prevention of cardiac fibrosis in a subject.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: November 19, 2019
    Assignee: TX MEDIC AB
    Inventors: Lars Bruce, Adam Bruce, Anders Waas
  • Patent number: 10478452
    Abstract: The invention relates to an antiviral pharmaceutical composition for topical use against those viruses with a lipid envelope, comprising, as active ingredients a cationic copolymer containing tertiary amine groups and a cationic surfactant containing quaternary ammonium groups.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: November 19, 2019
    Assignee: QUIMICA LUAR SRL
    Inventors: Luis Alberto Argañarás, Roxana Valeria Alasino, Dante Miguel Beltramo
  • Patent number: 10478453
    Abstract: The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: November 19, 2019
    Assignee: Exela Pharma Sciences, LLC
    Inventors: John Maloney, Aruna Koganti, Phanesh Koneru
  • Patent number: 10478454
    Abstract: The invention discloses aluminium oxyhydroxide for use in the treatment and prevention of AD.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: November 19, 2019
    Assignee: AFFIRIS AG
    Inventors: Markus Mandler, Achim Schneeberger, Arne Von Bonin, Frank Mattner, Walter Schmidt
  • Patent number: 10478455
    Abstract: Tetrathiomolybdate is for use in therapy of a condition requiring reduced metabolism of an organ or whole body, e.g. myocardial infection, stroke or ischaemia-reperfusion injury.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: November 19, 2019
    Assignee: UCL BUSINESS LTD
    Inventors: Mervyn Singer, John Francis Martin, Alex Peter Dyson
  • Patent number: 10478456
    Abstract: The present invention relates to a pharmaceutical preparation for treating an inflammatory condition, preferably a condition associated with ischemia comprising: a) a physiological solution comprising peripheral blood mononuclear cells (PBM-Cs) or a subset thereof, or b) a supernatant of the solution a), wherein the solution a) is obtainable by cultivating PBMCs or a subset thereof in a physiological solution free of PBMC-proliferating and PBMC-activating substances for at least 1 h.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: November 19, 2019
    Assignee: APOSCIENCE AG
    Inventor: Hendrik Jan Ankersmit
  • Patent number: 10478457
    Abstract: The present invention provides a chimeric protein having the formula: Casp-Ht1-Ht2 wherein Casp is a caspase domain; Ht1 is a first heterodimerization domain; and Ht2 is a second heterodimerization domain and wherein, in the presence of a chemical inducer of dimerization (CID), an identical pair of the chimeric proteins interact such that Ht1 from one chimeric protein heterodimerizes with Ht2 from the other chimeric protein, causing homodimerization of the two caspase domains. The invention also provides a cell comprising such a protein and its use in adoptive cell therapy.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: November 19, 2019
    Assignee: UCL BUSINESS LTD
    Inventors: Martin Pulé, Ryan Trowbridge, Edward Hodgkin
  • Patent number: 10478458
    Abstract: Disclosed is a composition including: an isolated in vitro pre-conditioned population of adult bone marrow derived mesenchymal stem cells (BMSCs), wherein the BMSCs express neuronal markers, and wherein the neuronal markers are PGP9.5, NSE, Tuj1, HuC/D and neuronal nitric oxide synthase (nNOS). Methods of preparing the BMSCs are also provided. In addition, the present disclosure is directed to a method of treating an enteric nervous system-related disorder including: administering to a subject in need thereof a pharmaceutical composition including the in vitro pre-conditioned BMSC population and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: November 19, 2019
    Assignees: THE JOHNS HOPKINS UNIVERSITY, UNION HOSPITAL, TONGJI MEDICAL COLLEGE, HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Xuhang Li, Xiaohua Hou, Rong Lin
  • Patent number: 10478459
    Abstract: The present invention relates to compositions and methods for cell transplantation. In particular, the present invention provides a composition with procoagulant cells and at least one factor Xa inhibitor, preferably rivaroxaban, as well as at least one thrombin inhibitor, preferably bivalirudin.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: November 19, 2019
    Assignee: UNIVERSITE CATHOLIQUE DE LOUVAIN
    Inventors: Xavier Stephenne, Etienne Sokal, Mustapha Najimi, Stéphane Eeckhoudt, Cédric Hermans
  • Patent number: 10478460
    Abstract: The present invention is drawn to novel methods of selecting mammals receptive to embryo transfers in order to improve reproductive efficiency and milk production of the mammals. The present invention encompasses three methods: (1) selecting from any group of mammals; (2) selecting from estrus-negative mammals; and (3) selecting from estrus-negative mammals and pooling the selected mammals with estrus-positive mammals. Also encompassed is a kit for selecting mammals receptive to embryo transfers.
    Type: Grant
    Filed: June 13, 2012
    Date of Patent: November 19, 2019
    Assignee: J.R. Simplot Company
    Inventors: Brady Hicks, Donna S. Clark
  • Patent number: 10478461
    Abstract: The invention describes methods and agents for improving cosmetic appearance, for promoting, improving or restoring health of cells and tissues, preferably skin, and more preferably, for restoring aged or damaged skin to a healthy appearance. The agents include compositions of cells, eggs, cell extracts, egg extracts, and extract components such as purified nucleic acids, polypeptides, lipids, carbohydrates or other natural products.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: November 19, 2019
    Assignee: REGENICS AS
    Inventors: Runhild Gammelsaeter, Jan Remmereit
  • Patent number: 10478462
    Abstract: The present invention relates to an agent for effectively suppressing an increase in a blood acetaldehyde level. More specifically, the present invention relates to an alcohol metabolism promoter comprising glycogen obtained from a Veneroida bivalve.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: November 19, 2019
    Assignee: NICHIREI BIOSCIENCES INC.
    Inventors: Kenichi Nagamine, Hideya Tanabe
  • Patent number: 10478463
    Abstract: An external-use agent for cleaning and caring ovaries, vagina and vulva, which is produced by medical raw materials consisting of propolis extract, zedoary oil, and mint leaf filtrate is provided. On the basis of different properties of each natural Chinese herbal material, using supercritical CO2 technology, separation and extraction, and low-temperature centrifugation are carried out respectively, and they are processed for preparation in a proportion, and then the membrane separation is performed, so that a spraying agent or a caring product is manufactured. It may be used alone in a female reproductive system for preventing the repeated infection and for achieving vulval bacteriostatic or antibacterial purposes and cleaning and deodorizing the vagina, eliminating vulval pruritus, and refreshing and moisturizing vulva and vagina etc., with good cleaning and caring functions and achieving a significant effect.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: November 19, 2019
    Inventor: Jianxue Wei
  • Patent number: 10478464
    Abstract: This invention relates to the use of plant extracts, compositions thereof, and compounds isolated from plant extracts or obtained from synthetic means thereof, for the treatment of diseases, disorders or symptoms thereof (e.g., proliferation disorders, cancer).
    Type: Grant
    Filed: January 14, 2010
    Date of Patent: November 19, 2019
    Inventors: Vipul C. Chitalia, Daniel Prabakaran, Ajit Bharti, Gamini S. Jayatilake, Xiong Fu
  • Patent number: 10478465
    Abstract: Herbal composition for the treatment and management of cancer and method of preparation are disclosed herein. The disclosed composition includes a combination of herb and mineral components that facilitate in inhibiting abnormal cell proliferation. The embodiments of the composition can thus be used in treatment of cancer and related morbidities. Also, disclosed herein is a method for inducing cytotoxicity in cancer cells.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: November 19, 2019
    Assignee: Muniyal Ayurvedic Research Centre
    Inventor: M Vijayabhanu Shetty
  • Patent number: 10478466
    Abstract: A topical composition comprising from about 0.05% to about 10.0% by weight of Arnica oil, from about 5.0% to about 20.0% by weight of a notoginseng herb comprising dammarane-type ginsenosides, from about 0.05% to about 10% by weight of a compound comprising cyclopentasiloxane, dimethicone crosspolymer, dimethicone/vinyl dimethicone crosspolymer, dimethiconol, and a cosmetically acceptable aqueous carrier.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: November 19, 2019
    Inventors: Peter Kennedy, Carolyn Shawn Murphy
  • Patent number: 10478467
    Abstract: A method for the treatment or prophylaxis of depressed mood is described, for subjects with increased MAO-A levels, subjects prone to excessive crying, or beyond 5-days postpartum. The subject is administered an antioxidant source on at least the first day of a 3 to 5 day regime; a tryptophan composition on the evening of the penultimate treatment day, simultaneously or following the antioxidant source; and a tyrosine composition the day after the tryptophan composition, on the final treatment day. The antioxidant source may comprise blueberries or another anthocyanin-containing fruit, vegetable, nut, legume, or a juice or extract thereof. Individuals with depressed mood due to perimenopause, due to an alcohol use disorder or withdrawal therefrom, or who are in a postpartum period up to or beyond 18-months, may benefit from the treatment regime. The described method can reduce the likelihood of advancing from depressed mood to postpartum depression in the postpartum period.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: November 19, 2019
    Assignee: Centre for Addiction and Mental Health
    Inventor: Jeffrey H. Meyer
  • Patent number: 10478468
    Abstract: Disclosed is a method for enhancing the effect of an immunotherapy for cancer in a subject, comprising administering to the subject an effective amount of a polysaccharide extract of Astragalus membranaceus. Also disclosed is a method for increasing a subject's pool of M1 macrophages, wherein the subject is suffering from one or more conditions associated with undesirable M2 macrophage activation, the method comprising administering to the subject an effective amount of a polysaccharide extract of Astragalus membranaceus.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: November 19, 2019
    Assignee: PHYTOHEALTH CORPORATION
    Inventors: Liang-Shun Wang, Chi-Tai Yeh, Chun-Hung Wu, Yi-Li Lee
  • Patent number: 10478469
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A? is a Stretcher unit, and p is from about 3 to about 5.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: November 19, 2019
    Assignee: SEATTLE GENETICS, INC.
    Inventors: Eric Sievers, Dana Kennedy
  • Patent number: 10478470
    Abstract: The present invention relates to a pharmaceutical composition containing leuprolide acetate and having both immediate and sustained release properties and, more specifically, to a pharmaceutical composition in which, on the basis of the total weight of active ingredients, leuprolide as an immediate release preparation is contained in 0.001 wt % to 25 wt %; and leuprolide contained in microspheres of a sustained release preparation is contained in 75 wt % to 99.999 wt %. The pharmaceutical composition of the present invention is characterized by satisfying both a drug immediate release property so as to realize the prompt exposure to a sufficient amount of drug at the early stage for expression of medicinal effects and a drug sustained release property for four weeks or longer, and the pharmaceutical composition is effective in the prevention and treatment of sex hormone-dependent positive or malignant diseases.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: November 19, 2019
    Assignee: SK CHEMICALS CO., LTD.
    Inventors: Hong Kee Kim, Kyu Ho Lee, Seok Hyun Hong, Yong-kyu Kwak, Ho Chul Shin, Hun-Teak Kim